LIPFENDRA / Enlicitide for treating primary hypercholesterolemia or mixed dyslipidemia

As of August 2026, MARA’s assessment finds LIPFENDRA / Enlicitide’s reimbursement risk concentrated in uncertainty, sensitivity, and broader impacts, with care pathway integration a strength; the current MARA Rating and full rationale are available in the report.

The assessment also weighs clinical effectiveness: how much additional benefit the drug demonstrated over the care patients already receive — the first question every payer asks. The strength recorded in care pathway integration carries weight because that domain asks how the drug fits into the way care is organised today; a treatment that demands new infrastructure or displaces an established pathway faces extra scrutiny.

Cardiology

This rating sits within MARA’s Cardiology coverage, alongside 24 other independently assessed treatments in the same area.

What payers will ask

Is the clinical benefit the kind payers reward? — Clinical effectiveness

Phase 3 trials demonstrate significant LDL-C reduction, comparable to existing PCSK9 inhibitors, but lack direct cardiovascular outcome data.

Does the economic case hold at the expected price? — Cost effectiveness

No cost-utility analysis, ICER, or economic model available for enlicitide.

Is there quality-of-life evidence payers weigh? — Quality of life

No HRQoL data or validated instruments reported in the pivotal trials.

Does the safety profile hold up for payers? — Safety and Adverse Effects

Comparable safety profile to placebo over 52 weeks, with some adverse events like diarrhea and dizziness more frequent in HeFH patients.

Was the drug compared against what payers expect? — Comparator Selection

Strong comparator strategy with placebo and oral nonstatin comparators, but lacks direct comparison with injectable PCSK9 inhibitors.

Is the population defined the way payers need it? — Patient Population and Subgroups

Representative of high-risk hypercholesterolemia and HeFH populations, but lacks market-specific efficacy data.

Does the drug fit how care is delivered and paid for? — Care Pathway Integration

Fits well into existing care pathways as an oral therapy, requiring minimal adjustments.

Are the wider system costs understood? — Resource Use and Cost Implications

No budget-impact or resource-use data available.

Would the evidence survive payer scrutiny? — Evidence Quality and Robustness

Strong phase 3 evidence with reproducible LDL-C lowering, but lacks long-term safety and cardiovascular outcome data.

How exposed is the case to uncertainty? — Uncertainty, Sensitivity, and Broader Impacts

High uncertainty in long-term outcomes and economic impacts due to lack of data.

Request the current rating

Be alerted when this rating changes:

Related Reimbursement Risk Assessments

Full Legal Disclaimer and Usage Terms

The MARA Rating® is an independent opinion of a drug’s market access pharma risk profile and is provided for informational purposes only—not as investment, medical, legal or any other type of advice. See our full disclaimer here.